Friday-Sunday, February 21-23, 2020, Miami, Florida

The Second Annual Miami General Medical Oncology Symposium

 

Dates
February 21-23, 2020

Location
JW Marriott Miami Turnberry
19999 West Country Club Drive
Miami, FL 33180
Hotel Phone: 305-932-6200

Meeting Room
King Ballroom (Conference Level)

Hotel Accommodations
A special discounted room rate of $339 (plus applicable tax and facilities fee) is available to conference attendees at the JW Marriott Miami Turnberry. Please see the Location tab for additional details.

 

Note from the Moderator

This coming February will mark the Second Annual General Medical Oncology Conference. This one-of-a-kind offering will span parts of 3 days and feature a stellar multidisciplinary faculty panel and a unique blend of short didactic presentations, lively moderated panel discussions and dedicated Q&A sessions. To augment the conference’s interactivity, each clinician will be provided with a specially configured iPad® to use throughout the program to participate in audience polling, view all the presentation slides and anonymously submit questions to the panelists for the Q&A. The conference’s educational design and the topics that will be discussed offer interested clinicians the opportunity to access the in-depth perspectives of some of the top minds in the field regarding significant new data sets, promising treatment strategies and key interdisciplinary management considerations in the care of patients with cancer.

So as you begin to make your plans for 2020, we hope you will join us in sunny South Florida for a learning experience unlike any other out there.

Moderator
Neil Love, MD
Research To Practice
Miami, Florida

Faculty:

Friday — 7:00 PM – 8:30 PM

Keynote Session: Chronic Lymphocytic Leukemia

Matthew S Davids, MD, MMSc
Assistant Professor of Medicine
Harvard Medical School
Director, DFCI Lymphoma BioBank
Associate Director, CLL Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Anthony R Mato, MD, MSCE
Associate Attending
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, New York

Kerry Rogers, MD
Assistant Professor in the Division of Hematology
The Ohio State University
Columbus, Ohio

Saturday — 8:00 AM – 4:45 PM

Colorectal and Gastric Cancer

Johanna Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

John L Marshall, MD
Chief, Hematology and Oncology
Director, Ruesch Center for the Cure
of GI Cancers
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Hepatocellular Carcinoma and Pancreatic Cancer

Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine
and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Vice-Chair and Section Lead
Division of Medical Oncology
Medical Director, Cancer Clinical Research Office
Senior Associate Consultant
Mayo Clinic
Phoenix, Arizona

Wells A Messersmith, MD
Professor and Head, Division of Medical Oncology
Associate Director for Translational Research
University of Colorado Cancer Center
Aurora, Colorado

Dermatologic Cancers

Jason J Luke, MD
Associate Professor and Director of the Cancer
Immunotherapeutics Center
University of Pittsburgh Medical Center and
Hillman Cancer Center
Pittsburgh, Pennsylvania

Jeffrey S Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, New York

Hodgkin and Non-Hodgkin Lymphomas

Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

Mitchell R Smith, MD, PhD
Professor of Medicine
Associate Center Director for Clinical Investigations
Director, Division of Hematology and Oncology
GW Cancer Center
Washington, DC

Diffuse Large B-Cell Lymphoma and CAR T-Cell Therapy

Jeremy Abramson, MD
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sonali M Smith, MD
Elwood V Jensen Professor of Medicine
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Acute Leukemias

Alexander Perl, MD
Associate Professor of Medicine
Perelman School of Medicine at the
University of Pennsylvania
Member, Leukemia Program
Abramson Cancer Center of the
University of Pennsylvania
Philadelphia, Pennsylvania

Eytan M Stein, MD
Assistant Attending Physician
Director, Center for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Gynecologic Cancers

Michael J Birrer, MD, PhD
Director, Winthrop P Rockefeller Cancer Institute
Director, Cancer Service Line
University of Arkansas
Little Rock, Arkansas

Kathleen Moore, MD
The Virginia Kerley Cade Endowed Chair in
Cancer Development
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor
Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

ER-Positive, HER2-Negative Breast Cancer

Erika Hamilton, MD
Director, Breast and Gynecologic
Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in
Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Associate Director for Clinical Research
Leader of the Breast Cancer Program
UT Health San Antonio
The University of Texas
MD Anderson Cancer Center
San Antonio, Texas

HER2-Positive and Triple-Negative Breast Cancer

Harold J Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Charles E Geyer Jr, MD
Deputy Director
Houston Methodist Cancer Center
Houston, Texas

Sunday — 7:45 AM – 1:00 PM

Prostate Cancer

Robert Dreicer, MD, MS
Section Head, Medical Oncology
Deputy Director
University of Virginia Cancer Center
Associate Director for Clinical Research
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair in
Genitourinary Cancers
Professor of Medicine
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Renal Cell Carcinoma and Bladder Cancer

William K Oh, MD
Chief, Division of Hematology and
Medical Oncology
Professor of Medicine and Urology
Ezra M Greenspan, MD Professor in Clinical
Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
Mount Sinai Health System
New York, New York

Daniel P Petrylak, MD
Professor of Internal Medicine (Medical
Oncology) and Urology
Yale University
New Haven, Connecticut

Head and Neck Cancer

Barbara Burtness, MD
Professor of Medicine (Medical Oncology)
Disease Aligned Research Team Leader
Head and Neck Cancers Program
Co-Leader, Developmental Therapeutics
Yale Cancer Center
New Haven, Connecticut

Tanguy Y Seiwert, MD
Director
Head and Neck Cancer Oncology Disease Group
Co-Director
Bloomberg-Kimmel Institute for Immunotherapy — HNC Program
Assistant Professor of Oncology and Otolaryngology
Johns Hopkins University
Baltimore, Maryland

Multiple Myeloma

Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

Paul G Richardson, MD
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Immune Checkpoint Inhibitors in Lung Cancer

Hossein Borghaei, DO, MS
Associate Professor
Chief, Thoracic Medical Oncology
Co-Leader, Thoracic Cancer Service Line
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Stephen V Liu, MD, PhD
Associate Professor of Medicine
Georgetown University Hospital
Washington, DC

Targeted Treatment of Lung Cancer

Leora Horn, MD, MSc
Ingram Associate Professor of Cancer Research
Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt University Medical Center
Nashville, Tennessee

Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York


 

Prior to the conference, Research To Practice invited participants to complete a survey about the composition of their clinical practice, the results of which have been tabulated and will be presented at the start of each module to provide a contextual framework. Afterward, the faculty will deliver short presentations on emerging clinical research and recently approved or investigational agents and strategies related to assigned topics. Throughout each presentation, Dr Love will interject questions, reveal interactive audience polling results and introduce other related topics and queries submitted using the iPads® provided. During the final segment, the faculty members will be asked to make short comments on controversial issues across the cancer care continuum, including interdisciplinary concerns, end-of-life planning, complementary therapies, psychosocial support and other relevant topics.

Friday, February 21st

6:30 PM Welcome Reception

7:00 PM – Keynote Session: Chronic Lymphocytic Leukemia (CLL)

  • Clinical implications of recent Phase III data sets comparing ibrutinib-based therapy to standard chemoimmunotherapy approaches for younger (ECOG-E1912) and older (Alliance A041202, iLLUMINATE) patients with treatment-naïve CLL
  • Efficacy and safety findings from the Phase III CLL14 trial evaluating venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for patients with treatment-naïve CLL and coexisting medical conditions; clinical implications of the recent FDA approval of this regimen
  • Pharmacodynamic and pharmacokinetic similarities and differences between acalabrutinib and ibrutinib and implications for the efficacy and tolerability of these agents
  • Published data from the Phase III ELEVATE-TN trial comparing obinutuzumab/chlorambucil, acalabrutinib/obinutuzumab and acalabrutinib monotherapy for patients with previously untreated CLL
  • FDA approval of acalabrutinib as monotherapy for CLL; patient selection for its use
  • Frequency of side effects (eg, hemorrhage, atrial fibrillation, hypertension, headache) observed in patients with CLL receiving acalabrutinib versus ibrutinib
  • Clinical and biologic factors influencing the selection of first-line treatment regimen for patients with newly diagnosed CLL requiring active therapy
  • Long-term outcomes of the Phase III MURANO trial comparing venetoclax/rituximab to bendamustine/rituximab for relapsed/refractory (R/R) CLL
  • Practical and supportive care considerations associated with the use of venetoclax in CLL
  • Key findings from the Phase III ASCEND trial comparing acalabrutinib to rituximab in combination with either idelalisib or bendamustine for patients with R/R CLL; ongoing Phase III ELEVATE-RR study of acalabrutinib versus ibrutinib for high-risk R/R disease
  • Mechanistic similarities and differences among approved and investigational PI3K inhibitors; current role of PI3K inhibition in the treatment paradigm for CLL
  • Ongoing randomized trials evaluating novel combination approaches for newly diagnosed CLL

Saturday, February 22nd

8:00 AM – Introduction and Overview

8:05 AM – Module 1: Colorectal and Gastric Cancer

  • Published research data exploring the correlation between tumor location and response to specific therapeutic interventions
  • Rational incorporation of EGFR antibodies, regorafenib and TAS-102 into current treatment algorithms for metastatic colorectal cancer (mCRC)
  • Available data with and potential role of TAS-102 in combination with other systemic agents in mCRC or in earlier disease stages
  • Published research findings from the Phase III BEACON CRC trial comparing encorafenib/cetuximab with or without binimetinib to irinotecan/cetuximab or FOLFIRI/cetuximab for patients with mCRC and BRAF V600E mutations
  • Available research findings guiding the FDA approvals of nivolumab, pembrolizumab and nivolumab/ipilimumab for patients with microsatellite instability (MSI)-high/mismatch repair-deficient mCRC; patient selection for anti-PD-1 monotherapy versus combined anti-PD-1/anti-CTLA-4 antibody therapy
  • Biologic rationale for, available data with and ongoing investigation of regorafenib in combination with nivolumab for patients with microsatellite-stable (MSS) mCRC
  • Design, eligibility criteria and key efficacy and safety findings from the Phase III KEYNOTE-062 trial evaluating pembrolizumab alone and in combination with chemotherapy as first-line therapy for advanced gastric/gastroesophageal junction (GEJ) cancer; current role of immune checkpoint inhibition for patients with metastatic gastric/GEJ cancer
  • Primary and secondary endpoints achieved in the Phase III TAGS study of TAS-102 for heavily pretreated metastatic gastric cancer; FDA approval and patient selection in routine practice
  • Results from the Phase III KEYNOTE-181 trial and FDA approval of pembrolizumab for progressive, PD-L1-positive advanced esophageal cancer
  • Available efficacy and safety findings from the Phase III ATTRACTION-3 trial comparing nivolumab to chemotherapy for unresectable advanced or recurrent esophageal cancer that is refractory to or intolerant of fluoropyrimidine with platinum-based therapy
  • Role of multiplex testing in CRC and gastroesophageal cancer and implications for nonresearch care

8:55 AM – Module 2: Hepatocellular Carcinoma (HCC) and Pancreatic Cancer

  • Clinical and biologic factors affecting selection of first-line treatment for HCC (eg, age, symptomatology, liver function)
  • Biologic rationale for, early trial data with and FDA breakthrough therapy designation for atezolizumab/bevacizumab as first-line therapy for advanced HCC
  • Available efficacy and safety results from the Phase III IMbrave150 trial documenting the benefit of atezolizumab in combination with bevacizumab as first-line therapy for advanced HCC
  • Key factors (eg, performance status, liver function, alpha-fetoprotein level, prior therapy) influencing the selection of treatment for patients who experience disease progression after first-line therapy
  • Available data with and patient selection for anti-angiogenic therapy (eg, regorafenib, cabozantinib, ramucirumab) for progressive metastatic HCC
  • Published data with and appropriate integration of anti-PD-1/PD-L1 antibodies into the care of patients with progressive metastatic HCC
  • Results from the Phase Ib KEYNOTE-524 trial/Study 116 evaluating pembrolizumab in combination with lenvatinib as first-line treatment for advanced unresectable HCC not amenable to locoregional treatment; FDA breakthrough therapy designation and developmental plans
  • Available safety and efficacy findings with and ongoing evaluation of combined anti-PD-1/PD-L1 and anti-CTLA-4 antibodies in HCC; FDA acceptance of supplemental Biologics License Application and priority review status for nivolumab with ipilimumab for advanced HCC previously treated with sorafenib
  • Use of contemporary chemotherapy regimens (mFOLFIRINOX, nab paclitaxel/gemcitabine) with or without radiation therapy as neoadjuvant treatment for resectable or borderline-resectable pancreatic adenocarcinoma (PAD)
  • Outcomes from and clinical implications of recent randomized Phase III trials evaluating adjuvant mFOLFIRINOX or nab paclitaxel/gemcitabine compared to gemcitabine alone for resected PAD
  • Design, entry criteria and key efficacy and safety findings from the Phase III POLO trial evaluating olaparib as maintenance therapy for patients with metastatic PAD and a germline BRCA mutation after first-line chemotherapy
  • FDA approval of maintenance olaparib for patients with metastatic PAD and a germline BRCA mutation after platinum-based chemotherapy; implications for genetic testing and routine practice

9:45 AM Break

10:00 AM – Module 3: Dermatologic Cancers

  • Published efficacy and safety data from the Phase III CheckMate 238 trial evaluating adjuvant nivolumab versus ipilimumab for patients with resected melanoma at high risk for recurrence
  • Key efficacy outcomes from the Phase III KEYNOTE-054 trial comparing adjuvant pembrolizumab to placebo after complete resection of high-risk Stage III melanoma; recent FDA approval of this approach
  • Design of, entry criteria for and primary efficacy and safety outcomes from the Phase III COMBI-AD study evaluating dabrafenib/trametinib as adjuvant treatment for high-risk melanoma with a BRAF V600 tumor mutation after surgical resection; FDA-approved dose, schedule and indication for adjuvant dabrafenib/trametinib
  • Clinical, biologic and practical factors influencing the decision to administer nivolumab, pembrolizumab or dabrafenib/trametinib as adjuvant therapy
  • Key efficacy and safety outcomes from the Phase III COLUMBUS trial evaluating the combination of encorafenib/binimetinib versus vemurafenib for patients with unresectable or metastatic melanoma with a BRAF V600 tumor mutation; FDA approval of encorafenib/binimetinib and clinical, biologic and practical factors affecting the selection of a specific BRAF/MEK inhibitor combination
  • Incidence, prevention and management of side effects and toxicities associated with available BRAF/MEK inhibitor combinations
  • Long-term efficacy outcomes with anti-PD-1/anti-CTLA-4 therapy in the first-line setting; impact of age/performance status, prior therapeutic exposure, symptomatology and other clinical factors on patient selection for anti-PD-1 monotherapy versus combination treatment
  • Optimal management of brain metastases in patients with melanoma
  • Emerging data from the Phase III IMspire150 trial evaluating atezolizumab in combination with vemurafenib/cobimetinib as first-line therapy for advanced melanoma with a BRAF V600 mutation
  • Design of, eligibility criteria for and key efficacy and safety outcomes of the Phase II EMPOWER-CSCC 1 trial evaluating cemiplimab in advanced cutaneous squamous cell carcinoma; clinical implications of the recent FDA approval of this agent
  • Current clinical management of advanced basal cell carcinoma; role of vismodegib and sonidegib
  • Available clinical trial data supporting the FDA approvals of avelumab and pembrolizumab for patients with metastatic Merkel cell carcinoma

10:50 AM – Module 4: Hodgkin and Non-Hodgkin Lymphomas

  • Clinical and research implications of Phase III trials (RELEVANCE, AUGMENT, MAGNIFY) evaluating the R2 regimen of lenalidomide/rituximab in newly diagnosed and R/R follicular lymphoma (FL); recent FDA approval of R2 for R/R FL and patient selection for this approach
  • Role of obinutuzumab-based induction and maintenance therapy for previously untreated FL; integration of obinutuzumab into current algorithms for treatment-naïve and R/R disease
  • Patient selection for PI3 kinase inhibition in R/R FL; comparative efficacy and tolerability of idelalisib, copanlisib and duvelisib
  • Early activity and safety data with ibrutinib alone or in combination with other systemic therapies for previously untreated mantle cell lymphoma (MCL); ongoing and planned Phase III trials (eg, TRIANGLE, SHINE, SYMPATICO)
  • Mechanistic and pharmacodynamic similarities and differences between ibrutinib, acalabrutinib and zanubrutinib; research database supporting the FDA approvals of acalabrutinib and zanubrutinib in R/R MCL and patient selection for their use
  • Quality and interpretation of PET scanning for patients with newly diagnosed Hodgkin lymphoma (HL) receiving response-adapted therapy in the community; implications for first-line decision-making
  • Role of brentuximab vedotin (BV) in combination with doxorubicin/vinblastine/dacarbazine as first-line therapy for advanced classical HL
  • Experience with North American patients in the ECHELON-1 trial and implications, if any, for the adoption of BV
  • Available activity and safety data with and ongoing evaluation of immune checkpoint inhibitors alone or in combination with other systemic approaches (eg, chemotherapy, BV) for patients with newly diagnosed or R/R HL
  • Recent FDA approval of BV in combination with chemotherapy for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas; diagnostic and clinical implications

11:40 AM – Module 5: Diffuse Large B-Cell Lymphoma (DLBCL)/Chimeric Antigen Receptor (CAR) T-Cell Therapy

  • Biology of CD19-targeted CAR T cells; manufacturing and administration processes for CAR T-cell therapy
  • Compositional and mechanistic similarities and differences between available (axicabtagene ciloleucel [axi-cel], tisagenlecleucel [tis-cel]) and investigational (lisocabtagene maraleucel [liso-cel]) CD19-directed CAR T-cell platforms with established efficacy in DLBCL
  • Longer-term follow-up from clinical trials establishing the efficacy and safety of axi-cel, tis-cel and liso-cel
  • Incidence, timing and severity of cytokine release syndrome and CAR T-cell-related encephalopathy syndrome with anti-CD19 CAR T-cell therapy
  • Optimal integration of CAR T-cell therapy into current treatment algorithms; role of the general medical oncologist in facilitating consideration of CAR T-cell therapy
  • Current understanding of potential clinical and biologic factors predictive of response or toxicity; mechanisms of resistance to CAR T-cell therapy and potential strategies to overcome them
  • Available efficacy and safety data leading to the FDA approval of polatuzumab vedotin in combination with bendamustine/rituximab for patients with R/R DLBCL after at least 2 prior therapies; optimal incorporation into current management algorithms
  • Early findings with polatuzumab vedotin in combination with R-CHP for patients with previously untreated DLBCL; ongoing Phase III POLARIX trial

12:30 PM Lunch

1:15 PM – Module 6: Acute Leukemias

  • Assessment, incidence and prognostic or predictive relevance of cytogenetic and other molecular biomarkers (eg, FLT3 mutations, IDH1/2 mutations) in acute myeloid leukemia (AML)
  • Published efficacy and safety data supporting the recent FDA approval of venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML who are not candidates for intensive induction chemotherapy
  • Available data with and emerging role of venetoclax in younger, healthy patients
  • Incidence of tumor lysis syndrome and other adverse events associated with the use of venetoclax in AML in clinical trials; application to routine practice and recommendations for venetoclax administration in the community
  • Clinical database underlying the FDA approval of midostaurin for patients with newly diagnosed AML with a FLT3 mutation; patient selection and optimal incorporation into current management
  • Available research data with gilteritinib for AML with a FLT3 mutation; recent FDA approval of gilteritinib for R/R disease and appropriate integration into routine practice
  • Published research database supporting the FDA approvals of the IDH inhibitors enasidenib and ivosidenib; recognition and management of common and less frequently occurring adverse events
  • FDA-endorsed use of blinatumomab for patients with minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission or with R/R disease
  • Available data with blinatumomab as postreinduction therapy for high- and intermediate-risk first relapse
  • Biologic rationale for the evaluation of CAR T-cell therapy in patients with ALL
  • FDA approval of tis-cel for pediatric and young adult patients with ALL that is refractory or in second or later relapse; integration into clinical practice
  • Ongoing clinical investigation of CAR T-cell therapy in adult populations

2:05 PM – Module 7: Gynecologic Cancers

  • Key outcomes from the Phase III SOLO-1 trial evaluating maintenance olaparib after first-line platinum-based chemotherapy for patients with advanced ovarian cancer and a BRCA mutation
  • Results and clinical implications of the Phase III PRIMA study evaluating maintenance niraparib after first-line platinum-based chemotherapy for patients with advanced ovarian cancer; benefit of niraparib maintenance in various patient subgroups in the study
  • Design, eligibility criteria and efficacy and safety data from the Phase III PAOLA-1 trial comparing olaparib in combination with bevacizumab to bevacizumab alone as maintenance therapy for patients with advanced ovarian cancer who responded to first-line treatment with platinum-based chemotherapy and bevacizumab
  • Available data from the Phase III VELIA trial evaluating the addition of veliparib to first-line chemotherapy and as maintenance for high-grade ovarian cancer
  • Long-term follow-up from pivotal clinical trials evaluating olaparib, rucaparib and niraparib for patients with platinum-sensitive or platinum-refractory recurrent disease
  • Incidence of MSI in patients with advanced gynecologic cancers; recommended testing algorithms and activity of anti-PD-1/PD-L1 antibodies in individuals with MSI-high and MSS disease
  • Data leading to the recent FDA approval of pembrolizumab/lenvatinib for patients with previously treated advanced MSS endometrial cancer who are ineligible for curative surgery or radiation therapy
  • Preliminary safety and efficacy associated with the use of the anti-PD-1 antibody dostarlimab in patients with advanced or recurrent endometrial cancer; ongoing evaluation and development plans
  • Efficacy and safety associated with the use of pembrolizumab in patients with advanced cervical cancer enrolled on the Phase II KEYNOTE-158 trial; FDA approval of pembrolizumab for PD-L1-positive recurrent or metastatic cervical cancer with disease progression on or after chemotherapy and patient selection for its use in routine practice
  • Mechanism of action of and published efficacy and safety outcomes with the use of tisotumab vedotin in R/R cervical cancer; ongoing and planned trials evaluating the role of tisotumab vedotin in R/R and previously untreated metastatic cervical cancer

2:55 PM Break

3:05 PM – Module 8: ER-Positive, HER2-Negative Breast Cancer (BC)

  • Design, eligibility criteria, primary and secondary endpoints and major clinical findings from the Phase III TAILORx intermediate-risk cohort
  • Implications of the TAILORx intermediate-risk cohort results for adjuvant treatment for pre- and postmenopausal patients with localized BC; utility of classic clinical features to complement 21-gene Recurrence Score® findings in various patient subsets
  • Available data with and current clinical role of genomic classifiers in patients with node-positive disease
  • Clinical factors affecting the use and selection of CDK4/6 inhibitors with endocrine therapy as first-line treatment for ER-positive metastatic BC (mBC) (eg, prior endocrine therapy, symptomatology, performance status, disease-free interval, sites of metastases)
  • Long-term follow-up data, including overall survival findings, with CDK4/6 inhibitors for premenopausal and postmenopausal patients; current clinical role
  • Recent FDA announcement of possible severe lung inflammation associated with CDK4/6 inhibitors; monitoring for and management of this and other toxicities in patients receiving these agents
  • Role of CDK4/6 inhibition in elderly patients with ER-positive mBC; unique administration, monitoring and/or toxicity management considerations
  • Factors influencing the optimal management of disease progressing on CDK4/6 inhibitors in combination with hormonal therapy
  • Design, eligibility criteria and key efficacy data from the Phase III SOLAR-1 trial evaluating alpelisib/fulvestrant versus fulvestrant alone for patients with a PIK3CA mutation after disease progression on first-line endocrine therapy; FDA approval and current clinical role

3:55 PM – Module 9: HER2-Positive and Triple-Negative BC

  • Key efficacy and safety results from the Phase III KATHERINE study of adjuvant T-DM1 versus trastuzumab for patients with HER2-positive primary BC and residual disease after preoperative therapy
  • Updated efficacy results of the Phase III APHINITY study; patient selection for pertuzumab as part of adjuvant treatment
  • Recently presented results from the randomized Phase II ATEMPT trial comparing adjuvant T-DM1 to paclitaxel/trastuzumab for Stage I HER2-positive BC; clinical implications
  • Optimal integration of postadjuvant neratinib into clinical algorithms; patient selection and clinical factors (eg, ER/PR status, tumor size, nodal status) guiding its use in practice
  • Available efficacy and safety findings from the Phase III NALA study of neratinib/capecitabine for patients with HER2-positive mBC; current nonresearch role of neratinib in metastatic disease
  • Structural makeup of and available efficacy and safety data with the antibody-drug conjugate trastuzumab deruxtecan for HER2-positive mBC; recent FDA approval of and patient selection for trastuzumab deruxtecan
  • Mechanism of action of and early activity and safety data with the selective HER2 inhibitor tucatinib; FDA breakthrough therapy designation for tucatinib in combination with trastuzumab/capecitabine for patients with progressive HER2-positive mBC based on the results of the pivotal Phase II HER2CLIMB trial
  • Design, eligibility criteria and key efficacy and safety findings from the Phase III IMpassion130 trial evaluating atezolizumab with nab paclitaxel as first-line therapy for metastatic triple-negative BC (TNBC)
  • FDA approval of atezolizumab/nab paclitaxel for patients with PD-L1-positive unresectable locally advanced or metastatic TNBC; integration into clinical practice
  • Available results from the Phase III KEYNOTE-522 trial documenting the benefit of neoadjuvant pembrolizumab with chemotherapy versus chemotherapy alone for TNBC
  • Phase III data sets supporting the FDA approvals for olaparib (OlympiAD) and talazoparib (EMBRACA) for patients with mBC and a BRCA germline mutation

4:45 PM Adjourn

Sunday, February 23rd

7:45 AM – Module 10: Prostate Cancer (PC)

  • Design, eligibility criteria and key efficacy and safety outcomes observed in the Phase III SPARTAN, ARAMIS and PROSPER trials evaluating apalutamide, darolutamide and enzalutamide, respectively, for patients with nonmetastatic castration-resistant PC (CRPC)
  • FDA approvals of apalutamide, darolutamide and enzalutamide for patients with nonmetastatic CRPC; patient selection for and practical integration of these agents
  • Design, entry criteria and primary and secondary endpoints of the Phase III ARCHES and TITAN trials assessing enzalutamide or apalutamide in combination with androgen deprivation therapy (ADT) compared to ADT alone for patients with metastatic hormone-sensitive PC (mHSPC); key efficacy and safety outcomes
  • Results from the Phase III ENZAMET study of enzalutamide in combination with ADT versus other nonsteroidal antiandrogens (eg, bicalutamide, nilutamide or flutamide) with ADT for patients with mHSPC
  • Key clinical and practical factors guiding the selection of docetaxel, abiraterone acetate, enzalutamide or apalutamide for patients with mHSPC
  • Efficacy and safety findings from the CARD study evaluating cabazitaxel versus alternative androgen receptor (AR)-targeted therapy (abiraterone or enzalutamide) for patients with mCRPC who had received docetaxel and experienced disease progression on a prior AR-targeted agent
  • Selection and sequencing of therapy for patients with mCRPC who have experienced disease progression on docetaxel and AR-targeted therapy
  • Research database examining the utility of AR splice variant 7 expression as a predictive marker for response to secondary hormonal therapy in patients with mCRPC; commercially available platforms and current clinical role
  • Clinical trial data with the use of olaparib, rucaparib and niraparib for patients with progressive mCRPC; FDA breakthrough therapy designations and ongoing investigation
  • Results from the Phase III PROfound trial evaluating olaparib versus enzalutamide or abiraterone for mCRPC after failure of prior hormonal therapy in patients with homologous recombination repair gene mutations; potential role of olaparib in clinical practice
  • Role of multiplex testing in PC and implications for routine patient care

8:35 AM – Module 11: Renal Cell Carcinoma (RCC) and Bladder Cancer

  • Major efficacy and safety findings from the pivotal Phase III CheckMate 214 trial evaluating nivolumab/ipilimumab versus sunitinib for treatment-naïve advanced RCC
  • Design, eligibility criteria and key efficacy and safety data from the Phase III KEYNOTE-426 and JAVELIN Renal 101 trials assessing pembrolizumab/axitinib and avelumab/axitinib, respectively, in the front-line setting; FDA approvals of these regimens and optimal integration into clinical practice
  • Published research data with and FDA approval of cabozantinib as first-line therapy; current role of tyrosine kinase inhibitor monotherapy for patients with newly diagnosed metastatic RCC (mRCC)
  • Clinical and biologic factors influencing the selection of first-line therapy for patients with newly diagnosed mRCC
  • Evidence-based and guideline-endorsed approaches to the treatment of mRCC progressing on first-line therapy
  • Design, entry criteria and key efficacy and safety findings from the Phase II KEYNOTE-057 trial of pembrolizumab for patients with BCG-unresponsive, high-risk non-muscle-invasive urothelial bladder cancer (UBC) who are ineligible for or elected not to undergo cystectomy
  • Recent FDA approval of pembrolizumab for high-risk non-muscle-invasive UBC that is unresponsive to BCG and integration into current care
  • Available data with and ongoing Phase III trials of other immune checkpoint inhibitors for patients with nonmetastatic UBC
  • Current indications for the use of anti-PD-1/PD-L1 antibodies in previously untreated metastatic UBC; significance of PD-L1 status and platinum eligibility
  • Optimal integration of anti-PD-1/PD-L1 antibodies into the management of progressive metastatic UBC
  • Rationale for targeting nectin-4 in UBC; structural components and mechanism of action of enfortumab vedotin
  • Design, eligibility criteria and key findings from the pivotal Phase II EV-201 trial evaluating enfortumab vedotin for patients with locally advanced or metastatic UBC who previously received immune checkpoint inhibitor therapy; recent FDA approval of enfortumab vedotin and current clinical role
  • Ongoing studies evaluating the use of enfortumab vedotin alone (EV-301) or in combination with other systemic therapies, including anti-PD-1/PD-L1 antibodies (EV-103)

9:25 AM – Module 12: Head and Neck Cancer

  • Mutational burden of squamous cell carcinoma of the head and neck (SCCHN) and biologic rationale for testing immune checkpoint inhibitors as a management option
  • Design, eligibility criteria and key primary and secondary endpoints achieved in the Phase III CheckMate 141 and KEYNOTE-040 trials evaluating nivolumab and pembrolizumab, respectively, for patients with previously treated recurrent or metastatic (R/M) SCCHN
  • FDA approvals of pembrolizumab and nivolumab for patients with R/M SCCHN; patient selection for and practical integration of these agents in this setting
  • Key safety and efficacy outcomes of the Phase III KEYNOTE-048 study assessing pembrolizumab as monotherapy or in combination with platinum chemotherapy and 5-FU as first-line treatment for R/M SCCHN
  • Ongoing Phase III studies investigating immune checkpoint inhibitor therapy as a component of adjuvant or neoadjuvant therapy for SCCHN
  • Oncogenic potential of NTRK gene fusions; identification of NTRK gene fusions as a tumor-agnostic marker for therapy
  • Frequency of NTRK gene fusions in various SCCHN subtypes; validated tools for assessment (eg, IHC, FISH, next-generation sequencing)
  • Available clinical trial data informing the FDA approvals of larotrectinib and entrectinib for patients with solid tumors with NTRK gene fusions
  • Antitumor activity of and durability of response with larotrectinib and entrectinib in patients with SCCHN; integration of these agents into current treatment algorithms for salivary gland tumors
  • Safety profile of TRK inhibitors; similarities and differences in the spectrum and frequency of adverse events between the different TRK inhibitors
  • Other novel strategies under investigation for SCCHN

10:15 AM Break

10:30 AM – Module 13: Multiple Myeloma (MM)

  • Available efficacy and safety findings with carfilzomib-based induction regimens; current indications, if any, for the use of carfilzomib in patients with newly diagnosed MM
  • Published research findings, ongoing investigation and current clinical role of daratumumab-based front-line regimens for patients eligible and ineligible for transplant
  • Evidence-based use and optimal selection of maintenance therapy for transplant-eligible and -ineligible patients
  • Clinical, biologic and practical factors influencing the selection, sequencing and combining of carfilzomib, pomalidomide, daratumumab, elotuzumab and ixazomib for patients with R/R MM
  • Biologic rationale for and published efficacy and safety findings with venetoclax in MM; correlation between t(11;14) status and response
  • Similarities and differences among various BCMA-targeted CAR T-cell therapy platforms under investigation in MM
  • Published efficacy and safety outcomes with and ongoing investigation of BCMA-targeted CAR T-cell therapies in MM; emerging results from the pivotal Phase II KarMMa study of idecabtagene vicleucel in R/R MM
  • Structural composition and mechanism of action of the BCMA-directed antibody-drug conjugate belantamab mafodotin
  • Design, eligibility criteria and available efficacy and safety results from the Phase II DREAMM-2 study evaluating belantamab mafodotin in R/R MM; FDA priority review of Biologics License Application and potential future role
  • Available research data with and ongoing evaluation of various anti-BCMA bispecific T-cell engagers (eg, AMG-420, CC-93269) in MM
  • Similarities and differences between iberdomide and other immunomodulatory agents; recorded activity and safety in patients with heavily pretreated disease, including that which is refractory to lenalidomide and pomalidomide

11:20 AM – Module 14: Immune Checkpoint Inhibitors in Lung Cancer

  • Design of, eligibility criteria for and key efficacy and safety findings from the Phase III PACIFIC trial evaluating the use of consolidation durvalumab after chemoradiation therapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC)
  • Efficacy and current role of durvalumab in prespecified subgroups (eg, PD-L1 status, disease with a targetable genomic alteration)
  • Key efficacy and safety findings from the Phase III IMpower133 trial evaluating carboplatin/etoposide with or without atezolizumab for untreated extensive-stage small cell lung cancer (SCLC); recent FDA approval of first-line carboplatin/etoposide/atezolizumab and appropriate integration into current SCLC management
  • Design, eligibility criteria and primary and secondary endpoints in the Phase III CASPIAN trial evaluating durvalumab with or without tremelimumab in combination with platinum-based chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage SCLC; similarities and differences between the designs of the CASPIAN and IMpower133 studies
  • Key efficacy and safety findings from the CASPIAN trial; potential clinical role of durvalumab/etoposide/platinum chemotherapy as front-line treatment for extensive-stage SCLC
  • Clinical and biologic factors affecting the selection of anti-PD-1/PD-L1 monotherapy versus combined chemotherapy/immune checkpoint inhibition for patients with nonsquamous and squamous metastatic NSCLC
  • Published findings from the Phase III CheckMate 227 trial documenting an overall survival advantage with nivolumab/low-dose ipilimumab versus chemotherapy as first-line treatment for patients with NSCLC and PD-L1 tumor expression ≥1%
  • Emerging safety and efficacy data from the Phase III CheckMate 9LA trial evaluating nivolumab/ipilimumab in combination with chemotherapy versus chemotherapy alone as first-line therapy for NSCLC
  • Design, eligibility criteria and emerging safety and efficacy data from the Phase III POSEIDON trial evaluating durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy versus chemotherapy alone as first-line therapy for patients with metastatic NSCLC

12:10 PM – Module 15: Targeted Treatment of Lung Cancer

  • Guideline-endorsed testing algorithms for patients with metastatic adenocarcinoma of the lung; validation of and indications, if any, for plasma assays to identify EGFR and other mutations/alterations
  • Optimal long-term treatment for patients with NSCLC with EGFR tumor mutations, including those with CNS metastases; documentation of an overall survival benefit with osimertinib as first-line therapy in the Phase III FLAURA study
  • Biologic rationale for the design of clinical trials combining EGFR- and VEGFR-targeted therapy; key findings from the Phase III RELAY study and potential ramifications for practice and future clinical trial design
  • Impact of the prior use of immune checkpoint inhibitors on the efficacy and tolerability of EGFR TKI therapy
  • Available clinical trial data informing the selection of first- and later-line therapy for patients with metastatic NSCLC and an ALK or ROS1 rearrangement
  • Published data supporting the FDA approval of dabrafenib/trametinib for patients with metastatic NSCLC with a BRAF V600E tumor mutation; integration into routine clinical practice
  • Available clinical trial data informing the FDA approvals of larotrectinib and entrectinib for patients with NTRK gene fusions
  • Frequency of NTRK gene fusions in patients with NSCLC and integration of larotrectinib and entrectinib into current algorithms
  • Structural compositions, pharmacology, pharmacokinetics and pharmacodynamics of the next-generation RET inhibitors selpercatinib and pralsetinib
  • Design, eligibility criteria and key efficacy and safety findings from the LIBRETTO-001 trial evaluating selpercatinib in the treatment of RET fusion-positive NSCLC; FDA breakthrough therapy designation and potential future role in practice

1:00 PM Adjourn

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, head and neck, gastrointestinal, genitourinary, dermatologic, gynecologic and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, lung, head and neck, gastrointestinal, genitourinary, dermatologic, gynecologic and select hematologic cancers, and refer appropriate patients for study participation.
  • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

Accreditation Statements
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit Designation Statements
This educational activity for 14 contact hours is provided by Research To Practice.

This activity is awarded 14 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

CME Credit Form
A credit form will be given to each participant at the conclusion of the activity.

CNE Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP, ACCME or the ANCC. Any off-label use as declared by the FDA will be identified.

Educational Support
This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Array BioPharma Inc, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Lilly, Merck, Novartis, Oncopeptides, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, and Taiho Oncology Inc.

Research To Practice CME/CNE Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

JW Marriott Miami Turnberry
19999 West Country Club Drive
Miami, FL 33180
Hotel Phone: 305-932-6200

Meeting Room
King Ballroom (Conference Level)

Room Reservations
A special discounted room rate of $339 plus applicable taxes and discounted facilities fee of $30 (includes access to the new waterpark) is available to conference attendees at the JW Marriott Miami Turnberry during the conference dates only, February 21-23 (checking out on Sunday).

Option 1:
Secure accommodations by contacting the JW Marriott Miami Turnberry directly at (800) 228-9290 or (305) 932-6200. A personal credit card will be required to secure accommodations. Please mention you are participating in the Second Annual Miami General Medical Oncology Symposium to receive the special group rate.

Option 2:
Secure accommodations online via our housing block link for conference attendees: https://book.passkey.com/go/GMOGeneralMedicalOncology

Room reservations must be made by Monday, February 17, 2020 (5:00 PM EST). A limited number of rooms are available, and we encourage you to make your reservations early. After February 17, 2020, the hotel will offer the best rates based on room availability.

Parking
Overnight discounted valet parking rate of $40.00 per night plus tax, per car is available for conference attendees. Guests are permitted unlimited in-and-out privileges. Daily parking is available to conference attendees at a discounted rate of $20.00 plus tax per car for 1 to 3 hours, $25.00 plus tax per car for 4 to 6 hours or $38 plus tax per car for 7 hours or more. Please note that unfortunately, due to regulatory reporting requirements, Research To Practice is unable to validate parking.





This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

Registration Fees

This event is free of charge for practicing physicians, fellows, nurses and other healthcare providers involved in the treatment of cancer.

For all other individuals, including industry professionals,* a conference registration fee of $850 is available through February 1, 2020 and then $950 after that day. All fees processed will be nonrefundable after January 30, 2020 (5:00 PM eastern standard time). To cancel your registration, please contact our Meeting Services department at Meetings@ResearchToPractice.com or call (800) 233-6153.



Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

I am employed by a for-profit organization, including a financial institution, biotech or pharmaceutical company.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.